Michael Gelband’s Avanos Medical AVNS Stock Holding History

Michael Gelband’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-19,100	Closed	-$635K	–	1955
2020 Q3	$635K	Buy	+19,100	New	+$610K	0.01%	891

Other funds holding AVNS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.5B AUM 83.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Michael Gelband's AVNS Position: Q2 2026 in Review

Michael Gelband sold out of Avanos Medical (AVNS) in Q2 2026, closing a stake of 421,504 shares — an estimated $5.91M sold.

Michael Gelband first reported a position in AVNS in Q1 2020 and held it in 19 quarters. The position peaked at $15.3M in Q2 2025. 284 funds tracked by Wall St. Rank hold AVNS as of Q2 2026.

Michael Gelband reported no remaining Avanos Medical position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 421,504 Avanos Medical shares in Q2 2026, an estimated $5.91M.
Michael Gelband first reported a position in Avanos Medical in Q1 2020 and held it in 19 quarters.
Michael Gelband's Avanos Medical position peaked at $15.3M in Q2 2025.
284 funds tracked by Wall St. Rank held Avanos Medical as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.